Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 10.89 is in line with its 5-year average of 11.41, near the low end of its 5-year range (2.32–44.46).
As of the fiscal period ended Tuesday, June 30, 2026. 22.27% below its 12-month average of 14.01.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.89.
QUICK RATIO (ACID-TEST)
10.89
QUICK RATIO (ACID-TEST) AVG TTM
14.01
QUICK RATIO (ACID-TEST) AVG 3Y
9.65
QUICK RATIO (ACID-TEST) AVG 5Y
11.41
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
-22.27%
CURRENT VS 3Y AVG
+12.81%
CURRENT VS 5Y AVG
-4.56%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.35
median of 870 covered companies
CURRENT VS SECTOR MEDIAN
+224.55%
vs the sector median at left
Entrada Therapeutics, Inc.
Market Cap
$210.41M
Quick Ratio (Acid-Test)
10.89
TTM Avg
14.01
3Y Avg
9.65
5Y Avg
11.41
Market Cap
$209.91M
Quick Ratio (Acid-Test)
5.72
TTM Avg
5.91
3Y Avg
5.85
5Y Avg
7.15
Market Cap
$210.98M
Quick Ratio (Acid-Test)
5.36
TTM Avg
6.17
3Y Avg
11.50
5Y Avg
11.99
Market Cap
$208.31M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
Quick Ratio (Acid-Test)
2.45
TTM Avg
2.08
3Y Avg
1.84
5Y Avg
1.77
Market Cap
$214.24M
Quick Ratio (Acid-Test)
5.13
TTM Avg
3.45
3Y Avg
2.59
5Y Avg
2.27
Market Cap
$214.46M
Quick Ratio (Acid-Test)
20.05
TTM Avg
17.55
3Y Avg
12.54
5Y Avg
12.54
Market Cap
$205.80M
Quick Ratio (Acid-Test)
17.38
TTM Avg
6.77
3Y Avg
6.87
5Y Avg
6.33
Market Cap
$215.07M
Quick Ratio (Acid-Test)
344.31
TTM Avg
177.51
3Y Avg
95.13
5Y Avg
76.52
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | $210.41M | 10.89 | 14.01 | 9.65 | 11.41 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 5.72 | 5.91 | 5.85 | 7.15 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | 5.36 | 6.17 | 11.50 | 11.99 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 2.45 | 2.08 | 1.84 | 1.77 |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 5.13 | 3.45 | 2.59 | 2.27 |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | 20.05 | 17.55 | 12.54 | 12.54 |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | 17.38 | 6.77 | 6.87 | 6.33 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 344.31 | 177.51 | 95.13 | 76.52 |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 4.07 | 3.65 | 6.88 | 10.38 |
Quick Ratio
10.89
Excludes inventory
Current Ratio
10.89
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 10.89 |
| 2026-03-31 | 13.90 |
| 2025-12-31 | 12.53 |
| 2025-09-30 | 14.08 |
| 2025-06-30 | 18.64 |
| 2025-03-31 | 21.88 |
| 2024-12-31 | 11.15 |
| 2024-09-30 | 6.59 |
| 2024-06-30 | 5.70 |
| 2024-03-31 | 2.38 |
| 2023-12-31 | 2.33 |
| 2023-09-30 | 2.32 |
| 2023-06-30 | 3.10 |
| 2023-03-31 | 2.94 |
| 2022-12-31 | 9.55 |
| 2022-09-30 | 10.89 |
| 2022-06-30 | 14.05 |
| 2022-03-31 | 17.68 |
| 2021-12-31 | 44.46 |
| 2021-09-30 | 17.26 |
| 2021-06-30 | 30.34 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 11.89 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
